- Home
- MDGL
as 05-16-2025 4:00pm EST
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 6.8B | IPO Year: | N/A |
| Target Price: | $420.63 | AVG Volume (30 days): | 361.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -17.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $200.08 - $377.46 | Next Earning Date: | 05-01-2025 |
| Revenue: | $317,383,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 264.55% | Revenue Growth (next year): | 67.21% |
Stock Insider Trading Activity of Madrigal Pharmaceuticals Inc. (MDGL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| CRAVES FRED B | MDGL | Director | Mar 12 '25 | Sell | $328.89 | 15,470 | $5,082,479.62 | 355,867 | |
| Dier Mardi | MDGL | SVP and CFO | Mar 10 '25 | Sell | $323.04 | 258 | $83,344.32 | 10,440 | |
| Waltermire Robert E. | MDGL | Senior VP, Chief Pharma Dev. | Mar 5 '25 | Sell | $340.42 | 14,113 | $4,817,103.60 | 14,018 | |
| Huntsman Carole | MDGL | Chief Commercial Officer | Mar 3 '25 | Sell | $323.86 | 1,834 | $597,839.68 | 9,467 | |
| Dier Mardi | MDGL | SVP and CFO | Mar 3 '25 | Sell | $324.71 | 1,961 | $637,248.06 | 10,440 | |
| Kelley Shannon T | MDGL | General Counsel | Mar 3 '25 | Sell | $335.00 | 415 | $139,025.00 | 7,290 | |
| Waltermire Robert E. | MDGL | Senior VP, Chief Pharma Dev. | Feb 28 '25 | Sell | $341.27 | 1,227 | $418,488.05 | 14,018 | |
| BATE KENNETH | MDGL | Director | Feb 27 '25 | Sell | $355.92 | 20,000 | $7,128,758.96 | 4,152 | |
| Daly James M | MDGL | Director | Feb 27 '25 | Sell | $347.75 | 15,470 | $5,375,125.55 | 1,912 |
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
GuruFocus.com
4 days ago
John Paulson's Strategic Move: Honeywell International Inc. Takes Center Stage
Motley Fool
6 days ago
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
GlobeNewswire
10 days ago
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
Insider Monkey
11 days ago
Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential
Insider Monkey
12 days ago
Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential
MT Newswires
17 days ago
UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating
GuruFocus.com
18 days ago
Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...
Thomson Reuters StreetEvents
18 days ago
Q1 2025 Madrigal Pharmaceuticals Inc Earnings Call
Compare MDGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.